← Eichor
Study identifier: NCT06620432 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

High vs. Low Segmental Hysterotomy: Impact on Uterine Wall Defects Post-Cesarean

Condition: Placenta Accreta Spectrum  ·  Sponsor: Fundacion Clinica Valle del Lili

PhaseNA
Planned participants168
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of this clinical trial is to compare the incidence of defects in the uterine wall at the site of the scar (niche) and surgical complications when using high-segment versus low-segment hysterotomy, with both cross-suturing and non-cross-suturing techniques, in pregnant patients undergoing their first cesarean section. Researchers will compare four arms: * Low Segment Hysterotomy + Crossed hysterorrhaphy * High Segment Hysterotomy + Crossed hysterorrhaphy * Low Segment Hysterotomy + Non-Crossed hysterorrhaphy * High Segment Hysterotomy + Non-Crossed hysterorrhaphy Participants will: * Cesarean delivery * Attend a follow up appointment between 6 to 16 weeks post surgery where will be perform a transvaginal sonography.

This description comes directly from the study's public registry record.

Talk to the study team

Albaro J. Nieto, M.D.  ·  3319090  ·  albaro.nieto@fvl.org.co

Always discuss trial participation with your own doctor first.

Locations (1)

Fundación Valle del LiliCali, Valle del Cauca Department, ColombiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06620432